Genzyme-Isis Cholesterol Drug + BIOGEN -ISIS receive up to an additional $259 million in a licensing fee
Isis stands to claim $25 million milestone if U.S. regulator approves new drug.
Crooke is also waiting to hear from regulators in Europe by the end of this year gives another $47million milestone payment. Both has option to get royalties to get another 5 Years.
•Isis formed a new strategic alliance with Biogen Idec to develop and commercialize a drug to treat DM1 that expands Isis' severe and rare disease franchise. Isis received a $12 million upfront payment and is eligible to receive up to an additional $259 million in a licensing fee and milestone payments. Isis will also receive double-digit royalties on product sales.